Obermatt

Ypsomed

SWX:YPSN · CH0019396990
Health Care Equipment & SuppliesMedium

360

29
EV / EBIT17
Price / Owner Earnings100
Owner Earnings Yield1
Dividend Yield61
Price/Sales12
EV / Gross Profit7
Price/Book26
Return on Capital97
Cash Return on Capital33
Return on Equity98
EBIT Margin100
Gross Profitability40
Cash Conversion23
Accruals64
Owner Earnings Margin35
Sales growth6
Profit Growth66
Long-Term EPS Growth83
Reinvestment70
Price momentum43
Debt load46
Refinancing66
Debt Payback1
Liquidity89
Analyst ratings48
Opinion Changes92
Price Target Upside26
Market mood53
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Ypsomed clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySwitzerland
IndustryHealth Care Equipment & Supplies
SizeMedium
TypePublic Company
ExchangeSWX
Employees1,069
ISINCH0019396990
Last UpdateApr 2, 2026
Themes
Injection MoldingChronic DiseasesBiomedical EngineeringDiabetesWearables

Description

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. Business Segments The company operates through two segments Ypsomed Delivery System…

Analysis

Hope premium

Ypsomed Holding AG is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium. Worth noting: the cash the business generates has lagged behind what the income statement shows.

Valuation data is not available for this company.

Growth is tepid; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
20
2023202420252026

All-time high

77

Jan 2025

All-time low

20

Jun 2026

Average rank

50

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
12
7
12
46
Price/Earnings
12
26
14
18
Price/Book
26
6
9
36
Dividend Yield
61
54
47
39
Value (overall)
26
16
7
15

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ypsomed with its peers
Convatec Group
LSE:CTEC
65
CountryUK
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
CENIT
GER:CSH
88
CountryGermany
IndustrySoftware
SizeSmall
Full Stock Analysis →
AlzChem Group
GER:ACT
57
CountryGermany
IndustryChemicals
SizeMedium
Full Stock Analysis →
Gjensidige Forsikring
OSL:GJF
78
CountryNorway
IndustryInsurance
SizeMedium
Full Stock Analysis →
UNIQA
VIE:UQA
46
CountryAustria
IndustryInsurance
SizeLarge
Full Stock Analysis →
Aegon
AEX:AGN
28
CountryNetherlands
IndustryInsurance
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →